2023-508444-22-01RecruitingPhase 1
An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 18 Apr 2024
- Start date
- 26 Aug 2024
- Lead sponsor
- Region Midtjylland
- Diseases
- Hepatitis B
- EU CT number
- 2023-508444-22-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 48
- 7 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR | Berlin | Germany | Recruiting |
| Aalborg University Hospital | Aalborg | Denmark | Recruiting |
| Region Midtjylland | Aarhus N | Denmark | Recruiting |
| Hvidovre Hospital | Hvidovre | Denmark | Recruiting |
| Rigshospitalet | København Ø | Denmark | Recruiting |
| Kolding Sygehus | Kolding | Denmark | Recruiting |
| Odense University Hospital | Odense C | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.